期刊
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS
卷 1182, 期 -, 页码 28-38出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2009.05075.x
关键词
interleukin; cytokine; T cell
资金
- NATIONAL CANCER INSTITUTE [ZIABC011074, ZIABC010960, ZIABC010957, ZIABC011072, ZIABC010525] Funding Source: NIH RePORTER
- Intramural NIH HHS [Z01 BC010525-05] Funding Source: Medline
Interleukin-7 has critical and nonredundant roles in T cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine. Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immuno-senescence), pathologic (HIV) or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant) and may have roles in immune reconstitution or enhancement of immunotherapy. Early clinical development trials in humans show that, within a short time, rhIL-7 administration results in a marked preferential expansion of both naive and memory CD4 and CD8 T cell pools with a tendency toward enhanced CD8 expansion. As a result, lymphopenic or normal older hosts develop an expanded circulating T cell pool with a profile that resembles that seen earlier in life with increased T cell repertoire diversity. These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据